Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non Operating Income (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Non Operating Income for 4 consecutive years, with $103000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 102.6% to $103000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 272.55% year-over-year, with the annual reading at $2.9 million for FY2025, 272.55% up from the prior year.
  • Non Operating Income for Q4 2025 was $103000.0 at Centessa Pharmaceuticals, up from -$1.8 million in the prior quarter.
  • The five-year high for Non Operating Income was $5.4 million in Q2 2022, with the low at -$4.0 million in Q4 2024.
  • Average Non Operating Income over 4 years is -$116375.0, with a median of -$474000.0 recorded in 2022.
  • The sharpest move saw Non Operating Income plummeted 1154.29% in 2023, then soared 2232.47% in 2025.
  • Over 4 years, Non Operating Income stood at -$70000.0 in 2022, then tumbled by 1154.29% to -$878000.0 in 2023, then tumbled by 351.94% to -$4.0 million in 2024, then soared by 102.6% to $103000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $103000.0, -$1.8 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.